Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06634693 · ClinicalTrials.gov registry record

Controlled Desaturation Study for TipTraQ SpO2 Performance Validation

A clinical trial of Hypoxia, sponsored by PranaQ Pte..

Completed
Registry status
12
Enrollment target
1
Study location

NCT06634693: Completed study of Hypoxia, sponsored by PranaQ Pte..

NCT06634693 is a study of Hypoxia that has completed, run by PranaQ Pte.. The registered enrollment target is 12 participants, below the 3,117-participant average among 39 other Hypoxia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06634693, a study of Hypoxia, has completed, sponsored by PranaQ Pte..

COMPLETED
Registry status
12 participants
Enrollment target
1
Study location

Study Summary

The objective is to validate the performance of SpO2 measurement of the TipTraQ by comparing it with measurement from an artery blood sample of a healthy volunteer in a controlled desaturation study. The overall framework of the validation process followed Annex EE.2 of ISO 80601-2-61:2019.

Primary Outcome

oxygen saturation of arterial blood sample measured by blood gas analysis

Conditions Studied

Study Locations (1)

California

  • UCSF Medical Center at Parnassus - San Francisco

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-10-10
Est. Completion 2023-10-11
PranaQ Pte.

2 total trials

What the finished NCT06634693 record still lists

NCT06634693 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 3,117-participant average among 39 other Hypoxia trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Hypoxia appearing as the primary indexed condition, and to 0 interventions.

NCT06634693 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06634693 about?

NCT06634693 is a clinical study titled "Controlled Desaturation Study for TipTraQ SpO2 Performance Validation". The objective is to validate the performance of SpO2 measurement of the TipTraQ by comparing it with measurement from an artery blood sample of a healthy volunteer in a controlled desaturation study. The overall framework of the validation process followed Annex EE.2 of ISO 80601-2-61:2019.

What is the current status of trial NCT06634693?

This trial is currently completed. The enrollment target is 12 participants. The study started on 2023-10-10. Estimated completion is 2023-10-11.

What conditions does trial NCT06634693 study?

This clinical trial studies the following conditions: Hypoxia.

Who is sponsoring clinical trial NCT06634693?

This trial is sponsored by PranaQ Pte., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06634693 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypoxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06634693's enrollment target sits among peer trials

12 30th of 39 higher than 3 of 39 other Hypoxia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypoxia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06634693, the US trial registry maintained by the National Library of Medicine. NCT06634693 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.